Ribavirin/Pegasys Treatment of Recurrent Hepatitis C After Liver Transplant
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to assess whether patients with recurrent hepatitis C after liver
transplantation will benefit from a treatment with ribavirin/PEG-IFN-alpha combined treatment
for 48 weeks.